APIGUARD
Diabetes
University of TaubateSmall moleculePhase 4 / ApprovedDormant
BB
65/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 54/ 100
- Competitive Position
- 81/ 100
Competitive context
36 Active assets in the Diabetes cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Humulin R Mostafa Bahaa | Phase 4 | BBB |
Semaglutide LMC Diabetes & Endocrinology Ltd. | Phase 4 | BB |
Ezetimibe University of Oxford | Phase 4 | BB |
Liraglutide University of Leicester | Phase 4 | BB |
Dapagliflozin Erbil Polytechnic University | Phase 4 | BB |
View all 50 →
Same molecule, other indications
APIGUARD is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →